Denmark’s Bavarian Nordic is the only lab producing a vaccine already specifically approved against monkeypox and has seen orders surge with the outbreak of the virus but is making sure it can meet all of them.
Also read: Monkeypox’s name is set to change soon and is considered misleading and stigmatizing by the WHO
“We can easily supply the world market”
Approval received (by US health authorities) in 2019 […] has suddenly become very, very relevant to international healthsmiles, at the biotech’s headquarters in the port of Copenhagen, its Vice President Rolf Sass Sørensen.
Surprised by the spread of the disease outside the 11 countries in West and Central Africa where it is endemic, Mr. Sass Sørensen nevertheless assures that he can meet the demand himself with a single production facility.
With the current demand, we can easily supply the global market. We have a few million doses in bulk, we can fill them and make sure the current outbreak is dealt withhe explains to himAFP.
Bavarian Nordic has an annual production capacity of 30 million cans at its plant north of the Nordic capital.
Its smallpox vaccine is a 3rd generation serum, ie live non-replicating vaccine (it does not replicate in the human body) marketed under the name Imvanex in Europe, where it has been approved since 2013 by Jynneos in the United States and Imvamune in Canada.
Initially indicated for adult smallpox, a disease thought to have been eradicated for about forty years, treatment requires two doses.
According to Mr. Sass Sørensen, the vaccine
in stock in many countries and it can be applied before or after contact with the disease.
If you get vaccinated a few days after exposure, you may also be protectedhe clarifies.
After receiving the green light from US authorities three years ago, Bavarian Nordic is working to expand its European registry for monkeypox.
100,000 vaccines bought by the European Union
Within the EU, the health authority Hera (founded in the wake of the Covid-19 pandemic) has bought almost 100,000 vaccines, which will be made available to the Twenty-Seven as well as Norway and Iceland.
First deliveries are expected for priority countries by the end of June, the European authorities said.
The United States also said it had replenished its stocks with an additional 500,000 doses in addition to 100 million units of another smallpox vaccine made by Sanofi of France. Canada and Denmark have done the same.
Apart from these announcements, the Danish laboratory jealously guards the nationality of its sponsors.
We don’t give out country names, but we have inquiries from all over the world: United States, European countries, Asia, Middle Eastsays Sass Sorensen.
The amounts of the contracts were also not published, but for Bavarian Nordic this is a stroke of luck that has allowed it to raise its forecast for 2022 four times in three weeks. Despite the exponential increase in cases, the WHO does not recommend vaccination
Celebration in this stadium.
In France, the High Health Authority has recommended the administration of a single dose of the vaccine to high-risk contacts who were vaccinated against smallpox before 1980, with the exception of immunocompromised individuals. The United States relies on vaccination of contact cases.
An anti-smallpox drug, Tecovirimat, made by the Siga lab, was approved by the EMA for monkeypox earlier this year but is not yet widely available.
Mostly mild, the illness usually resolves spontaneously, after two to three weeks with flu-like symptoms, followed by skin rashes.
From January 1 to June 15, more than 2,103 cases and one death were reported to the WHO in 42 countries. Europe is at the center of the spread of the virus, with 1,773 confirmed cases, or 84% of the global total.
In addition to the smallpox vaccine, Bavarian Nordic also produces vaccines against tick-borne encephalitis, rabies, Ebola and develops sera against Covid-19 and RSV respiratory viruses.